Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON34339
NL-OMON34339
Recruiting
Not Applicable

the pharmaprofile; towards tailor-made pharmacotherapy for the terminally ill adult patient. - Pharmaprofile terminally ill adult

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites150 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionspalliatieve zorg, terminale ziektecomfortpalliative sedation

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
palliatieve zorg, terminale ziekte
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
150
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\-Terminal illness
  • •\-Prognosis survival more than 2 days and less than 3 months
  • •\-Administration of morphine, haloperidol and/or midazolam
  • •\-Informed consent

Exclusion Criteria

  • •\-Withdrawal of informed consent
  • •\-No blood sample obtained

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 2
Clinical Efiicacy of Marichyadi Lepa and Abhayarishta on Shvitra (Vitiligo)
CTRI/2017/02/007929IPGT and RA60
Completed
Not Applicable
Development of patient individualization medication method of ampicillin/sulbactam and vancomycin when cardiovascular surgerycardiovascular surgery condition
JPRN-UMIN000007356Kagoshima University hospital50
Active, not recruiting
Not Applicable
Individualised drug therapy based on pharmacogenomics: focus on carboxylesterase 1 (CES1) - INDICES/WP2Healthy volunteers with special genotypesMedDRA version: 16.0Level: LLTClassification code 10053349Term: Pharmacokinetic studySystem Organ Class: 100000004848Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
EUCTR2011-004815-22-DKResearch Institute of Biological Psychiatry Sct. Hans
Completed
Not Applicable
therapeutic drug monitoring: towards tailored dosing of adalimumab in rheumatoid arthritisrheumatoide arthritis10003816
NL-OMON41716Reade, centrum voor Revalidatie en Reumatologie55
Completed
Not Applicable
Study for personalized medicine based on pharmacokinetics and pharmacodynamics concerned with therapeutic drug of nontuberculous mycobacterium.
JPRN-UMIN000020406Center for Infectious Disease and Infection Control10